WallStSmart

Merck & Company Inc (MRK)vsPerrigo Company PLC (PRGO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 1429% more annual revenue ($65.01B vs $4.25B). MRK leads profitability with a 28.1% profit margin vs -33.5%. PRGO appears more attractively valued with a PEG of 1.14. MRK earns a higher WallStSmart Score of 59/100 (C).

MRK

Buy

59

out of 100

Grade: C

Growth: 4.0Profit: 9.5Value: 4.7Quality: 4.8
Piotroski: 3/9

PRGO

Hold

48

out of 100

Grade: D+

Growth: 2.0Profit: 3.5Value: 7.0Quality: 5.5
Piotroski: 4/9Altman Z: 0.39
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKOvervalued (-13.2%)

Margin of Safety

-13.2%

Fair Value

$96.48

Current Price

$109.18

$12.70 premium

UndervaluedFair: $96.48Overvalued
PRGOUndervalued (+82.2%)

Margin of Safety

+82.2%

Fair Value

$81.94

Current Price

$11.29

$70.65 discount

UndervaluedFair: $81.94Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK6 strengths · Avg: 9.2/10
Market CapQuality
$274.03B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
36.9%10/10

Every $100 of equity generates 37 in profit

Operating MarginProfitability
32.8%10/10

Strong operational efficiency at 32.8%

Profit MarginProfitability
28.1%9/10

Keeps 28 of every $100 in revenue as profit

P/E RatioValuation
15.2x8/10

Attractively priced relative to earnings

Free Cash FlowQuality
$1.82B8/10

Generating 1.8B in free cash flow

PRGO1 strengths · Avg: 10.0/10
Price/BookValuation
0.5x10/10

Reasonable price relative to book value

Areas to Watch

MRK3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
3.362/10

Expensive relative to growth rate

EPS GrowthGrowth
-19.3%2/10

Earnings declined 19.3%

PRGO4 concerns · Avg: 2.3/10
Market CapQuality
$1.55B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-38.7%2/10

ROE of -38.7% — below average capital efficiency

Revenue GrowthGrowth
-2.5%2/10

Revenue declined 2.5%

EPS GrowthGrowth
-63.6%2/10

Earnings declined 63.6%

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.

Bull Case : PRGO

The strongest argument for PRGO centers on Price/Book. PEG of 1.14 suggests the stock is reasonably priced for its growth.

Bear Case : MRK

The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.

Bear Case : PRGO

The primary concerns for PRGO are Market Cap, Return on Equity, Revenue Growth.

Key Dynamics to Monitor

MRK profiles as a value stock while PRGO is a turnaround play — different risk/reward profiles.

PRGO carries more volatility with a beta of 0.49 — expect wider price swings.

MRK is growing revenue faster at 5.0% — sustainability is the question.

MRK generates stronger free cash flow (1.8B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (59/100 vs 48/100), backed by strong 28.1% margins. PRGO offers better value entry with a 82.2% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Perrigo Company PLC

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Perrigo Company plc is an American Irish registered manufacturer of private label over-the-counter pharmaceuticals.

Visit Website →

Want to dig deeper into these stocks?